Search results
Showing 1006 to 1020 of 1251 results for public health guidance
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued Reference number: GID-TA10711
In development Reference number: GID-TA11345 Expected publication date: TBC
In development Reference number: GID-MT594 Expected publication date: TBC
Discontinued Reference number: GID-TA11181
Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]
Discontinued Reference number: GID-TA11175
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Discontinued Reference number: GID-TA11018
Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the ARCHITECT and ALINITY i Urine NGAL assays, BioPorto NGAL test and NephroCheck test.
In development Reference number: GID-TA11014 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]
In development Reference number: GID-TA11015 Expected publication date: TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]
In development Reference number: GID-TA11629 Expected publication date: TBC
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]
Discontinued Reference number: GID-TA11712
In development Reference number: GID-TA11679 Expected publication date: TBC
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]
Discontinued Reference number: GID-TA11522
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
In development Reference number: GID-TA11646 Expected publication date: TBC